Dr. Howard Smith Oncall

New Immunotherapy For Nasty Cancers

Informações:

Sinopsis

Vidcast:  https://www.instagram.com/p/C3Gc6AXrwP1/ Pancreatic and bowel cancers are two of the most difficult to treat, but they often sport a unique marker that can serve as a target for killer T cells.  Oncologists at New York’s Memorial Sloan Kettering Cancer Center and Texas’ MD Andersons Cancer Center have led a collaborative study showing that the KRAS gene marker which appears in 93% of pancreatic cancers and 50% of colorectal cancers can serve as the basis for new vaccine against these cancers. In a human phase 1 study, 20 patients with pancreatic cancer and 5 patients with bowel cancer unresponsive to other therapies received an anti-KRAS protein vaccine without undesirable side effects.  84% of the treated group developed detectable T cell immunity against the KRAS gene and that same percentage had measurable reduction in circulating KRAS tumor antigen.  24% of patients had complete elimination of these KRAS biomarkers. Those patients with the best anti-KRAS immune responses were still living lon